Start-Up Tries Crowdfunding To Revive Brain Cancer Drug Berubicin
Executive Summary
Emerging Company Profile: Texas start-up CNS Pharmaceuticals sees a bright future for blood-brain barrier-crossing berubicin, which is nearing the end of its patent life.
You may also be interested in...
Immuno-Oncology Outlook: Looking For Brain Cancer Options
Scrip analyses the potential of "hot" immunotherapy mechanisms, such as PD-1 inhibitors and CAR-T therapies, in various stages of clinical development for glioblastoma.
Avastin QoL Data In First-Line Glioblastoma Muddy Expansion Plans
Genentech’s bevacizumab was associated with improved maintenance of baseline quality of life and performance status in a confirmatory trial conducted under accelerated approval, but an NCI-funded study found higher rates of neurocognitive decline, increased symptom severity and decline in health-related quality of life.
R&D Realities Disturb Dreams About Orphan Brain Cancer Blockbusters
Developing drugs for the rare, aggressive glioblastoma, the most common and malignant type of glioma, or brain cancer, was never easy. But a brain cancer drug’s journey through Phase III and to the finish line of market entry today is more arduous than ever.